Merck, one of the world's largest vaccine makers, will work with Johnson & Johnson to boost supply of its single-shot vaccine, President Joe Biden's administration announced March 2.
Under the agreement, Merck will dedicate two of its U.S. facilities to producing Johnson & Johnson’s vaccine. One will produce doses, and the other will be for filling the vials with the vaccine and packaging them before distribution.
Merck discontinued the development of its two COVID-19 vaccine candidates Jan. 25.
More articles on pharmacy:
How J&J's COVID-19 vaccine compares to Moderna's, Pfizer's
Pharmacy operator to pay Roche $43M to settle fraudulent rebates lawsuit
Florida expands eligibility for COVID-19 vaccines at retail pharmacies, physician offices